Single-dose and multi-dose delivery systems for an intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 10, 2012, Pages 751-759

  Nave, Rüdiger ^a   Connolly, Sandra M ^b   Popper, Lars ^c   Lahu, Gezim ^a   Schmitt, Holger ^a  

^a Nycomed a Takeda Company   (Germany)

^b CELERION   (United States)

^c Nycomed Denmark   (Denmark)

Author keywords

Breakthrough pain; Cancer patients; Dose delivery system; Fentanyl; Intranasal administration

Indexed keywords

FENTANYL; NALTREXONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BODY WEIGHT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRANASAL SPRAY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PALATE DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; UVULA EDEMA; VITAL SIGN;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 84867270710     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201729     Document Type: Article

References (27)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990; 41: 273-281. doi:10.1016/0304-3959(90)90004-W PubMed (Pubitemid 20187930)
2. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009; 13: 331-338. doi:10.1016/j.ejpain.2008. 06.014 PubMed
3. Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother. 2003; 4: 493-502. doi:10.1517/14656566.4.4.493 PubMed (Pubitemid 36511979)
4. Patt RB, Ellison NM. Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology (Williston Park). 1998; 12: 1035-1046., discussion 1049-1052. PubMed
5. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000; 20: 87-92. doi:10.1016/S0885-3924(00)00161-5 PubMed
6. Gómez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M, Alcalde R, Planas J, Camell H. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002; 24: 45-52. PubMed
7. Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F; Research Steering Committee of the EAPC. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med. 2005; 19: 477-484. doi:10.1191/ 0269216305pm1054oa PubMed (Pubitemid 41430821)
8. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 Management. Pharm Ther. 2005; 30: 354-361. (Pubitemid 40885216)
9. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983; 8: 422-446. doi:10.2165/00003088- 198308050-00004 PubMed (Pubitemid 13009122)
10. Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med. 2003; 17: 219-221. doi:10.1191/0269216303pm755oa PubMed (Pubitemid 36432601)
11. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002; 46: 759-770. doi:10.1034/j.1399-6576.2002.460702.x PubMed (Pubitemid 34803193)
12. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage. 2000; 20: 253-258. doi:10.1016/S0885-3924(00)00180-9 PubMed
13. Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008; 30: 469-481. doi:10.1016/j.clinthera.2008.03.001 PubMed (Pubitemid 351483922)
14. Foster D, Upton R, Christrup L, Popper L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. 2008; 42: 1380-1387. doi:10.1345/aph. 1L168 PubMed
15. Nave R, Sides EH, Colberg T, et al. Higher systemic bioavailability and faster absorption of intranasal spray (INFS) compared to Actiq (OTFC) in healthy subjects. Poster presented at the 6th Congress of the European Federation of IASP Chapters (EFIC), Lisbon, Portugal, September 9th-12th, 2009
16. Nave R, Sides EH, Colberg T, et al. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. Poster presented at the 6th Congress of the European Federation of IASP Chapters (EFIC), Lisbon, Portugal, September 9th-12th, 2009.
17. Nave R, Sides EH, Colberg T, et al. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Poster presented at the 6th Congress of the European Federation of IASP Chapters (EFIC), Lisbon, Portugal, September 9th-12th, 2009.
18. Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag. 2010; 6: 17-26. doi:10.5055/jom.2010.0001 PubMed
19. Kaessner, N, Nave R, Roepcke S et al. Population pharmacokinetic metaanalysis for intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. Int. J Clin Pharmacol Ther. 2012; 50: 665-667. DOI 10.5414/CP201737
20. Kress HG, Oroñska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009; 31: 1177-1191. doi:10.1016/j.clinthera.2009.05.022 PubMed
21. Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009; 25: 2805-2815. PubMed
22. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Helsinki 1964, amended in Tokyo 1975, Venice 1983, Hong Kong 1989, South Africa 1996, Edinburgh 2000, Washington 2002, Tokyo 2004
23. FDA. Guidance for Industry. Statistical approaches to establishing bioequivalence. U.S. Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 2001; http://www.fda.gov/cder/guidance/index.htm.
24. EMA. Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1) London 24 July 2008
25. FDA. Guidance for Industry. Bioanalytical Method Validation. May 2001 U.S. Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001 http://www.fda.gov/cder/guidance/index.htm.
26. Agu RU, Ugwolke MI. In Situ and Ex-vivo Nasal Models for Preclinical Drug Development Studies, in: Drug Absorption studies: In situ, in vitro and in silico models, C. Ehrhardt and K.J. Kim,(Eds), Springer 2008; 216-234.
27. Chaushu G, Bercovici M, Dori S, Waller A, Taicher S, Kronenberg J, Talmi YP. Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer. 2000; 88: 984-987. doi:10.1002/(SICI)1097-0142(20000301)88: 5〈984::AID-CNCR6〉3.0.CO;2-0 PubMed (Pubitemid 30127656)